Madrigal Pharmaceuticals Reports 2018 First Quarter Financial Results and Reviews Key Clinical AchievementsMay 8, 2018
Madrigal Pharmaceuticals Reports 2017 Fourth Quarter and Year-End Financial ResultsMarch 13, 2018
Madrigal’s MGL-3196 Achieves Primary Endpoint in Patients with Heterozygous Familial Hypercholesterolemia (HeFH)February 8, 2018
Press Release History
Website Developed by Alan Leff Associates, Inc.